NCT01723696

Brief Summary

Vitamin C supplementation (500 mg per day) given to pregnant women who can not quit smoking will improve the pulmonary function tests in their offspring measured at 3 months of age.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
252

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Dec 2012

Longer than P75 for phase_2

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 6, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 8, 2012

Completed
23 days until next milestone

Study Start

First participant enrolled

December 1, 2012

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2016

Completed
1.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

April 17, 2019

Completed
Last Updated

April 17, 2019

Status Verified

March 1, 2019

Enrollment Period

3.3 years

First QC Date

November 6, 2012

Results QC Date

October 15, 2018

Last Update Submit

March 28, 2019

Conditions

Keywords

In-utero smoke;Pulmonary function testing;Wheeze;Vitamin C;Forced expiratory flows

Outcome Measures

Primary Outcomes (1)

  • Forced Expiratory Flow at 75% of Expired Volume (FEF75)

    The primary outcome was the comparison of infant FEFs at 3 months of age obtained using the raised volume rapid thoracic compression (RVRTC) technique in offspring of pregnant smokers randomized to vitamin C versus placebo. The specific primary outcome parameter was the measurement of FEF at 75% of the expired volume (FEF75)

    3 months of age

Secondary Outcomes (2)

  • Forced Expiratory Flow at 75% of Expired Volume (FEF75)

    12 months of age

  • Incidence of Wheezing Through 12 Months of Age

    12 months of age

Study Arms (2)

placebo tablet+prenatal vitamin

PLACEBO COMPARATOR

A daily placebo tablet

Dietary Supplement: Placebo tablet+prenatal vitamin

Vitamin C +prenatal vitamin

ACTIVE COMPARATOR

500 mg vitamin C /day

Dietary Supplement: Vitamin C +prenatal vitamin

Interventions

Vitamin C +prenatal vitaminDIETARY_SUPPLEMENT

Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo

Also known as: Ascorbic acid
Vitamin C +prenatal vitamin
placebo tablet+prenatal vitamin

Eligibility Criteria

Age15 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Singleton gestation
  • ≥ 15 years old
  • Gestational age between 13 and 22 weeks
  • Receiving prenatal care
  • Current smoker
  • English speaking

You may not qualify if:

  • Gestational age ≥ 23 and 0/7 weeks
  • Multiple gestation
  • Major fetal congenital anomalies
  • Current use of illicit drugs
  • Current alcohol abuse
  • Use of vitamin C (≥ 500 mg/day)\>3 days per week since last menstrual period
  • Refusal to abstain from vitamin or supplements containing significant vitamin C other than those provided through or approved by study staff
  • History of kidney stone in patient
  • Insulin dependent diabetes
  • Complex maternal medical conditions
  • Participation in other conflicting research projects
  • Unable to demonstrate stable method of communication
  • Pregnancy by in-vitro fertilization
  • Plan to terminate pregnancy
  • Failure of medication compliance trial
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Indiana University

Indianapolis, Indiana, 46202-5167, United States

Location

Oregon Health & Science University

Portland, Oregon, 97239, United States

Location

Related Publications (4)

  • Shorey-Kendrick LE, McEvoy CT, Milner K, Harris J, Brownsberger J, Tepper RS, Park B, Gao L, Vu A, Morris CD, Thompson EE, Ober C, Spindel ER. Vitamin C supplementation to pregnant smokers alters asthma- and allergy-associated CpGs in child buccal DNA at 5 years of age. Clin Epigenetics. 2025 Oct 3;17(1):155. doi: 10.1186/s13148-025-01965-2.

  • Shorey-Kendrick LE, McEvoy CT, Milner K, Harris J, Brownsberger J, Tepper RS, Park B, Gao L, Vu A, Morris CD, Spindel ER. Improvements in lung function following vitamin C supplementation to pregnant smokers are associated with buccal DNA methylation at 5 years of age. Clin Epigenetics. 2024 Feb 27;16(1):35. doi: 10.1186/s13148-024-01644-8.

  • Shorey-Kendrick LE, McEvoy CT, O'Sullivan SM, Milner K, Vuylsteke B, Tepper RS, Haas DM, Park B, Gao L, Vu A, Morris CD, Spindel ER. Impact of vitamin C supplementation on placental DNA methylation changes related to maternal smoking: association with gene expression and respiratory outcomes. Clin Epigenetics. 2021 Sep 19;13(1):177. doi: 10.1186/s13148-021-01161-y.

  • McEvoy CT, Shorey-Kendrick LE, Milner K, Schilling D, Tiller C, Vuylsteke B, Scherman A, Jackson K, Haas DM, Harris J, Schuff R, Park BS, Vu A, Kraemer DF, Mitchell J, Metz J, Gonzales D, Bunten C, Spindel ER, Tepper RS, Morris CD. Oral Vitamin C (500 mg/d) to Pregnant Smokers Improves Infant Airway Function at 3 Months (VCSIP). A Randomized Trial. Am J Respir Crit Care Med. 2019 May 1;199(9):1139-1147. doi: 10.1164/rccm.201805-1011OC.

MeSH Terms

Conditions

Antisocial Personality DisorderRespiratory Sounds

Interventions

Ascorbic Acid

Condition Hierarchy (Ancestors)

Personality DisordersMental DisordersSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Sugar AcidsAcids, AcyclicCarboxylic AcidsOrganic ChemicalsHydroxy AcidsCarbohydrates

Results Point of Contact

Title
Cindy McEvoy, MD
Organization
OHSU

Study Officials

  • Cynthia T McEvoy, MD,MCR

    Oregon Health and Science University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Pediatrics

Study Record Dates

First Submitted

November 6, 2012

First Posted

November 8, 2012

Study Start

December 1, 2012

Primary Completion

April 1, 2016

Study Completion

December 1, 2017

Last Updated

April 17, 2019

Results First Posted

April 17, 2019

Record last verified: 2019-03

Locations